Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (251-260 of 383) with videos related to

Pageof 39
Sort By:
Blood|March 9, 2006
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461, Sherif S Farag, Kellie J Archer, et al.
Blood|November 11, 2006
End points to establish the efficacy of new agents in the treatment of acute leukemiaFrederick R Appelbaum, Daniel Rosenblum, Robert J Arceci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502Eyal C Attar, Jeffrey L Johnson, Philip C Amrein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B studyGuido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
Blood Advances|October 17, 2017
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with <i>FLT3</i>-mutated acute myeloid leukemia: CALGB 11001Geoffrey L Uy, Sumithra J Mandrekar, Kristina Laumann, et al.
Leukemia Research|November 13, 2021
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trialSelina M Luger, Victoria X Wang, Jacob M Rowe, et al.
Haematologica|April 15, 2024
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantationGregory W Roloff, Satyajit Kosuri, Mariam T Nawas, et al.
Cancer|January 3, 2014
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808Jonathan E Kolitz, Stephen L George, Don M Benson, et al.
Haematologica|January 29, 2026
Hematologic complications in patients exposed to poly-ADP ribose polymerase inhibitorsJoseph M Cannova, Muriel R Battaglia, Gregory W Roloff, et al.
Blood Cancer Journal|February 19, 2021
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradicationPin Lu, Shengchun Wang, Carrie A Franzen, et al.
Pageof 39

Showing results (251-260 of 383) with videos related to

Sort By:
Pageof 39
Blood|March 9, 2006
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461, Sherif S Farag, Kellie J Archer, et al.
Blood|November 11, 2006
End points to establish the efficacy of new agents in the treatment of acute leukemiaFrederick R Appelbaum, Daniel Rosenblum, Robert J Arceci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502Eyal C Attar, Jeffrey L Johnson, Philip C Amrein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B studyGuido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
Blood Advances|October 17, 2017
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with <i>FLT3</i>-mutated acute myeloid leukemia: CALGB 11001Geoffrey L Uy, Sumithra J Mandrekar, Kristina Laumann, et al.
Leukemia Research|November 13, 2021
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trialSelina M Luger, Victoria X Wang, Jacob M Rowe, et al.
Haematologica|April 15, 2024
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantationGregory W Roloff, Satyajit Kosuri, Mariam T Nawas, et al.
Cancer|January 3, 2014
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808Jonathan E Kolitz, Stephen L George, Don M Benson, et al.
Haematologica|January 29, 2026
Hematologic complications in patients exposed to poly-ADP ribose polymerase inhibitorsJoseph M Cannova, Muriel R Battaglia, Gregory W Roloff, et al.
Blood Cancer Journal|February 19, 2021
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradicationPin Lu, Shengchun Wang, Carrie A Franzen, et al.
Pageof 39